Peptides

SS-31 (Elamipretide)

A peptide that goes directly to your mitochondrial inner membrane — the exact place where cellular energy is made. SS-31 is further along in clinical development than most peptides, with Phase II/III trials for rare mitochondrial diseases.

Emerging Subcutaneous injection Mitochondrial energy 4 min read

SS-31 (also called elamipretide or Bendavia) is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane — specifically binding to cardiolipin, a phospholipid critical for energy production. It stabilises the electron transport chain, reduces oxidative stress at the source, and has actual clinical trial data behind it.

Route
Subcutaneous injection
Common dose
40 mg/day (clinical trials)
Research stage
Phase II/III clinical trials
Legal status (India)
Investigational — research chemical

Who's interested: People with mitochondrial dysfunction, those interested in cellular energy optimisation, and longevity enthusiasts following the mitochondrial theory of aging.

Dive deeper into the research

Potential side effects

  • Injection site reactions (most common in trials)
  • Mild headache reported in some trial participants
  • Generally well-tolerated in clinical studies
See all side effects

What does SS-31 do?

Your mitochondria generate energy through a process called oxidative phosphorylation — a chain of protein complexes in the inner mitochondrial membrane that pass electrons to generate ATP (your cellular fuel). This process is incredibly efficient but also produces reactive oxygen species (ROS) as a byproduct.

As you age, this system becomes leakier — producing more ROS and less ATP. SS-31 targets this exact problem. It binds to cardiolipin, a phospholipid found only in the inner mitochondrial membrane, and stabilises the electron transport chain. Less leakage means less oxidative damage and more efficient energy production.

What sets SS-31 apart from most peptides: it has actual clinical trial data. It's been tested in humans for Barth syndrome (a genetic mitochondrial disease), heart failure, and age-related macular degeneration.

Who uses it?

What to know before trying

Context

SS-31 has more clinical data than most experimental peptides — Phase II/III trials with safety and efficacy data. However, it's not approved for general use. Its clinical development is focused on rare mitochondrial diseases, not longevity per se.

Tracking a peptide protocol?

eterni connects your labs, supplements, and retests — so you can see whether your protocol is actually working.

Get early access

Frequently Asked Questions

What makes SS-31 different from other mitochondrial supplements?

Most mitochondrial supplements (CoQ10, NMN, PQQ) work indirectly — providing cofactors or precursors. SS-31 goes directly to the inner mitochondrial membrane and binds cardiolipin, physically stabilising the electron transport chain where energy is actually made. This targeted mechanism is unique among available compounds.

Has SS-31 been tested in humans?

Yes. SS-31 (elamipretide) has been through Phase II and III clinical trials for Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related macular degeneration. It showed improvements in exercise capacity and cardiac function in some trials, though results have been mixed.

Is SS-31 available in India?

SS-31 is available as a research peptide from some online vendors, though fewer carry it compared to more popular peptides. It is not approved as a drug or supplement in India. Quality varies significantly — pharmaceutical-grade is preferred but difficult to obtain outside of clinical trials.

Can SS-31 reverse aging?

In animal studies, SS-31 reversed some age-related mitochondrial changes — improving cardiac function, skeletal muscle performance, and kidney function in aged mice. Whether this translates to meaningful anti-aging effects in humans is unknown. It addresses one aspect of aging (mitochondrial dysfunction) but aging is multi-factorial.

Research & Science

How it works in your body

Clinical trial results

Side effects & safety

SS-31 has better safety data than most experimental peptides thanks to clinical trials:

Who should avoid it: People with active cancer, pregnant or breastfeeding women, and those on medications that affect mitochondrial function without consulting a doctor.

Which labs to monitor

Know what's working. Know what's not.

eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.

Join the waitlist

Related